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b2-Adrenoceptors are widely distributed and occur on airway epithelial cells. The aim of
this study was to find out whether the two long-acting b2-agonists formoterol and
salmeterol influence interleukin-6 (IL-6) and -8 (IL-8) release from airway epithelial cells
in vitro.
A549 cells and primary bronchial epithelial cells (PBEC) were stimulated with organic dust
from pig barns. Non-stimulated and dust-stimulated cells were incubated for 24 h with
formoterol or salmeterol (1013–106 M) and the release of IL-6 and IL-8 into the medium
was assessed by ELISA technique. Propranolol (105 M) or sotalol (103 M) were used to
block the b2-agonist mediated effects.
Formoterol and salmeterol both induced enhancement of IL-6 and IL-8 release and added
to the effect of organic dust. This enhanced release was blocked by a b-blocker in PBEC but
not in A549 cells.
To our knowledge, this is the first time b2-agonists have been shown to stimulate IL-6
release from airway epithelial cells. The results indicate different mechanisms of
b2-agonist action in bronchial and alveolar epithelial cells. Furthermore, our results
indicate that A549 cells do not possess functional b2-adrenoceptors.
& 2006 Elsevier Ltd. All rights reserved.Introduction
b2-Adrenoceptors are widely distributed throughout the
human respiratory system and are present on a variety of
cells, such as smooth muscle cells, alveolar type II cells,
mast cells, lung epithelial and endothelial cells.1 Stimula-Elsevier Ltd. All rights reserved.
24 822 03; fax: +46 8 300 619.
i.se (K. Strandberg).tion of airway b2-adrenoceptors induces relaxation of airway
smooth muscle and interacts with epithelial cells by
increasing ciliary beat frequency and affecting ion transport
across the cells by opening apical ion channels.2 b2-Agonists
also regulate cytokine release and have been shown to
enhance release of interleukin (IL)-8 from bronchial epithe-
lial cells3 and airway smooth muscle cells.4
Exposure of healthy subjects in swine confinement
buildings induces increased bronchial responsiveness to
direct stimuli such as methacholine5 and histamine6 and an
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inflammatory cells, predominantly neutrophils, as assessed
by bronchoalveolar lavage. Exposure also leads to systemic
effects such as fever, chills, increased serum levels of acute
phase proteins and blood leukocytosis.7 Following 3 h of
exposure in a swine barn the levels of pro-inflammatory
cytokines (tumour necrosis factor (TNF), IL-1, IL-6 and IL-8)
are elevated in nasal and bronchoalveolar lavage fluids, and
the concentration of TNF and IL-6 increases in peripheral
blood.8–10 Dust collected in swine houses has been shown to
activate human airway epithelial cells and alveolar macro-
phages and is a very potent stimulus for cytokine release in
those cells in vitro.11–14
Long-acting b2-agonists are widely used in the treatment
of obstructive airway diseases and have been shown to
interact with inflammatory mechanisms in asthma. Asthma
exacerbations are often induced by airway infections and it
seems reasonable to assume that the intensified airway
inflammation observed in patients with acute asthma, in
particular when induced by microbial agents, is in part a
consequence of activation of the innate immune system.
The effects of b2-agonists on inflammatory mechanisms
specific for asthma and allergy have been previously
studied, whereas the interaction between b2-agonists and
the innate immunity is less clear. From a clinical perspective
it is recognized that inhalation of b2-agonists may be less
beneficial during a prolonged, infection-induced asthma
exacerbation than during an acute asthma attack induced by
triggers such as exercise or cold air. Patients with acute
asthma attacks and patients with severe asthma have a
significantly greater number of neutrophils in their sputum
than patients with mild-to-moderate asthma.15
The aim of the present study was therefore to find out
whether long-acting b2-agonists (formoterol and salmeterol)
are capable of influencing cytokine release induced by a
non-allergic stimulus in airway epithelial cells in vitro. For
this purpose two different types of airway epithelial cells
were used; a human lung carcinoma alveolar type II
epithelial cell line (A549) and primary bronchial epithelial
cells (PBEC) isolated from tissue obtained at lung surgery. As
it has been previously demonstrated that organic dust from
swine barns induces cytokine release from A549 cells (see
above), this stimulus was used in the present study.Material and methods
Stimulus and drugs
Settled dust was collected approximately 1.2m above the
floor in a swine confinement building with 300–400 pigs. The
dust was dissolved in the cell growth medium, 1mg/ml, and
sonicated (Eurosonic, Medelco AB, Stockholm, Sweden) for
10min.
The drugs were generous gifts from Astra Zeneca AB,
Lund, Sweden (formoterol), GlaxoSmithKline, Uxbridge,
Middlesex, UK (salmeterol) and NM Pharma, Stockholm,
Sweden (sotalol). Propranolol was purchased from Sigma-
Aldrich, Stockholm, Sweden.
Stock solutions were prepared as follows. Formoterol was
dissolved in 0.01M HCl (104 M), salmeterol was dissolved
in phosphate buffer/saline (102 M), sotalol (1.0M) andpropranolol (0.1M) were dissolved in water. The stock
solutions were kept at 70 1C until used. At the time of
each experiment, stock solutions were diluted in cell growth
medium to achieve final concentrations.
Lung carcinoma epithelial cell line (A549)
Cells from the human lung carcinoma epithelial cell line
A549 (American Type Culture Collection, Rockville, USA)
were cultured. A total of 1.5–2 106 cells were seeded into
80 cm2 plastic flasks (Nunc, Roskilde, Denmark) and grown in
Ham’s F-12-medium with 10% heat-inactivated fetal calf
serum (Seromed Biochrom KG, Berlin, Germany) and 1%
penicillin/streptomycin. The cultures were kept at 37 1C in
humidified atmosphere of 5% CO2 in air and the medium was
changed every second day. At confluence the cells were
detached by exposure to trypsin/EDTA solution (0.05%/
0.02% in calcium- and magnesium-free phosphate buffered
saline; Biochrom KG) and reseeded in 6-well plates (Nunc,
Roskilde, Denmark) at a concentration of 3 105 cells/well
and grown to 80% confluence. The cells were washed twice
with serum-free F-12 medium before the experiments.
Primary bronchial epithelial cells (PBEC)
Establishment of the PBEC was modified after van Weter-
ing.16 Bronchial tissues were obtained from patients who,
due to lung cancer, underwent lobectomy or pulmectomy at
the Karolinska University Hospital in Stockholm, Sweden. All
subjects gave their informed and written consent and the
study was approved by the Ethics Committee of Karolinska
Institutet, Stockholm. A piece of a central, macroscopically
normal, bronchus was excised and immediately put in ice-
cold PBS buffer without calcium and magnesium (Gibco,
Paisley, Scotland, UK), trimmed, washed and incubated in
0.02% protease (Protease XIV; Sigma-Aldrich, Steinheim,
Germany) for 2 h at 37 1C. Epithelial cells were gently
scraped off from the luminal surface, washed once and
cultured in serum-free keratinocyte medium (keratinocyte-
SFM; Gibco) into 6-well plates (Nunc, Roskilde, Denmark).
The plates were pre-coated for 2 h with a combination of
vitrogen 30 mg/ml (Cohesion Technologies, Palo Alto, CA,
USA), fibronectin 10 mg/ml (Gibco), bovine serum albumin
10 mg/ml (BSA; Boeringer Mannheim, Mannheim, Germany)
and penicillin/streptomycin 20U/ml (BioWhittaker,
Walkersville, MD, USA) in PBS buffer without calcium and
magnesium. The serum-free keratinocyte medium was
supplemented with epidermal growth factor (EGF) 5 ng/ml
(Gibco), bovine pituitary extract (BPE) 50 mg/ml (Gibco),
isoproterenol 1 mM (Sigma-Aldrich) and penicillin/strepto-
mycin 20U/ml. During the first week of culture ciprofloxacin
10 mg/ml (a generous gift from Bayer; Wuppertal, Germany)
was added to the medium to assure the absence of
Mycoplasma.
The PBEC were cultured at 37 1C in humidified atmosphere
of 5% CO2 in air and the medium was changed every second
day. After reaching confluence, the PBEC were trypsinized
(trypsin 0.03% (w/v) (B&D, Sparks, MD, USA); EDTA 0.01%
(w/v); and glucose 0.1% (v/v) in PBS without calcium and
magnesium, pH 7.5), centrifuged, dissolved in freezing
medium (keratinocyte-SFM; Gibco with 10% DMSO and
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experiments, 2.5 105 cells were seeded into 64 cm2 pet-
ridishes (Costar) and grown in serum-free keratinocyte
medium supplemented with EGF 5 ng/ml, BPE 50 mg/ml
and penicillin/streptomycin 20U/ml; otherwise grown and
trypsinized under the same conditions as described above.
The cells were reseeded either into 24-well plates (Nunc) at
a seeding density of 3.5 104 cells/well or into 6-well plates
at a seeding density of 0.9–2 105 cells/well, grown to 80%
confluence and washed twice with PBS without calcium and
magnesium before the experiments. The experiments were
performed with cells at the second or third passage. Tests
for Mycoplasma contamination (SVA, Uppsala, Sweden) were
negative.
Immunostaining
Immunostaining was performed to establish epithelial origin
of the cells. Two different antibodies were used to
demonstrate cytokeratin expression, and one was used to
exclude fibroblast contamination. The cells were cultured at
cover slips, grown to 80% confluence and fixed with
methanol and BSA (1%) was used to block unspecific binding.
The primary antibodies used were monoclonal mouse anti-
pan cytokeratin IgG (Oncogene Science Inc., Cambridge, MA,
USA) 1:20 (recognizes human cytokeratin 1, 4, 5, 6, 8, 10,
13, 18 and 19), monoclonal mouse anti-human cytokeratin
Clone MNF116 (Dako, A/S Denmark) 1:50 (recognizes human
cytokeratin 5, 6, 8, 17 and 19) and mouse IgG Fibroblast
antigen (Ab-1) (Oncogene Research Products, San Diego, CA,
USA) 1:50. Secondary antibody was FITC conjugated mouse
immunoglobulin (Dako, A/S Denmark). The cover slips were
embedded in fluorescent mounting medium (Dako, A/S
Denmark) and viewed under a fluorescence microscope
(Labphot-2, Nikon FX-35DX).
Experimental design
Characterization of PBEC
Dose–response curves were established by stimulation of the
cells with increasing concentrations of the dust (0.1, 1, 10
and 100 mg/ml) followed by measurement of IL-6 and IL-8
release in the supernatant.
Time–response curves were established by culturing PBEC
in the presence and absence of the dust (100 mg/ml) for 2, 6,
8, 12 and 24 h. The IL-6 and IL-8 content in supernatant was
then analysed.
Drug experiments
Non-stimulated or dust (100 mg/ml) stimulated A549 or PBEC
were incubated for 24 h with formoterol or salmeterol at a
concentration of 1013–106 M in a dose–response manner.
Sotalol (103 M) or propranolol (105 M) were used to block
effects mediated by the b-agonists. In the experiment
including b-blockers these drugs were added to the wells 1 h
prior to other stimuli/drugs, and the incubation continued
for 24 h. After the incubation, the supernatants were
collected and centrifuged at 1000g for 10min to remove
cell debris, and stored at 70 1C until analysis. Cells were
detached by exposure to trypsin/EDTA solution, and cell
viability (Trypan blue exclusion, 0.4% in saline; Sera-Lab,Sussex, UK) was determined for every stimuli or drug
combination. The viability was 93–100%. Control experi-
ments with the diluents corresponding to the highest
concentration of each drug were performed to find possible
non-specific effects on the cytokine release by the diluents.
No such effects were observed (data not shown).
Each experiment was performed at least three times in
triplicates. PBEC cells from three donors were used for the
formoterol and salmeterol experiments.Cytokine assays
The IL-6 and IL-8 concentrations were determined by ELISA
methods developed in our laboratory.17 Commercially
available antibody pairs were used. The monoclonal anti-
human capture antibodies MAB206 (IL-6) and MAB208 (IL-8)
and the detection biotinylated anti-human polyclonal
antibodies BAF206 (IL-6) and BAF208 (IL-8) (R&D Systems
Europe) were used. The recombinant human standard for
IL-6 was 206-IL-010 and for IL-8 208-IL-010 (R&D Systems
Europe). Absorbance was read at 450 and 650 nm with a
Thermomax 250 reader (Molecular Devices, Sunnyvale, CA,
USA). Serum controls at three different concentrations were
used as calibrators in both methods and production was
expressed as pg/ml.
For duplicates an intra-assay coefficient of variation of
o10% and an inter-assay coefficient of variation of o20%
was accepted. The detection ranges for IL-6 and IL-8 assays
were 3–375 pg/ml and 50–3200 pg/ml, respectively.Statistics
The results are presented as mean7SEM. Since the absolute
response to dust stimulation may differ between experi-
ments the results are expressed as changes from negative
(medium) and positive (dust) controls. Comparisons were
assessed by analysis of variance (ANOVA) and Student’s
paired t-test. For statistical calculations, concentration
values below the detection limit were assigned a value of
1.5 pg/ml for IL-6 and 30 pg/ml for IL-8. A p-value below
0.05 was considered statistically significant. Statistical
analysis was performed using the StatViews program,
version 4.02 (Abacus Concepts Inc., Berkeley, CA, USA).Results
Characterization of the cells
Morphologically, both the A549 cells and the PBEC exhibited
a characteristic tight pavement-like appearance with poly-
gon-shaped cells growing in well-circumscribed patches.
Both cell types were positively stained with the two
different anti-cytokeratin antibodies unique for cells of
epithelial origin, and negatively stained with antibodies
directed against vimentin presented in fibroblasts.
Dust-induced cytokine responses in A549 cells showed a
close correlation when expressed as pg/ml and pg/106 cells
(r ¼ 0:98 for both IL-6 and IL-8, Fig. 1). Hence, for practical
reasons, cytokine concentrations are expressed as pg/ml.
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Figure 1 Comparison between cytokine concentrations ex-
pressed as pg/ml and pg/106 cells. The solid line represents the
identity line. The degree of explanation is 98% for both IL-6 and
IL-8 concentration corresponding to r ¼ 0:99 for both IL-6 and
IL-8.
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In non-stimulated PBEC the IL-6 concentration was below
detection limit after 2 h and 1673.3 pg/ml after 24 h of
incubation with medium. Corresponding IL-8 concentrations
were 5477.8 pg/ml after 2 h and 555799 pg/ml after 24 h
of incubation (Fig. 2a and b).
In dust-stimulated cells the IL-6 level was 3172.4 pg/ml
after 2 h and 188726 pg/ml after 24 h, and the correspond-
ing levels for IL-8 were 336728 pg/ml and 1051771511 pg/
ml, respectively. The concentrations of IL-6 and IL-8 were
significantly higher ðpo0:0001Þ after dust stimulation
compared to non-stimulated cells at all time points tested
(Fig. 2). The onset of IL-6 release preceded that of IL-8 in
PBEC (Fig. 2). After 6 h of incubation the IL-6 level had
reached 63% and the IL-8 level 27% of the response observed
after 24 h of dust incubation. The corresponding figures
after 12 h of dust incubation were 92% for IL-6 and 77% for
IL-8. There was no clear dose–response relationship for dust-
induced IL-6 release in PBEC below a dust concentration
of 10 mg/ml. There was a 12-fold increase of the IL-6
concentration at the highest dust concentration (100 mg/ml,
Fig. 2c) and dust-induced IL-8 release showed a dose–r-esponse relationship with a 22-fold increase at the highest
dust concentration (100 mg/ml, Fig. 2d).
Effect of b-agonists on IL-6 and IL-8 release
Non-stimulated A549 cells
In A549 cells formoterol did not significantly affect the IL-6
release at any concentration, whereas the IL-8 increased in a
dose–response manner (F ¼ 11:1, p ¼ 0:003, Fig. 3). Salme-
terol significantly increased IL-6 (F ¼ 8:54, p ¼ 0:004) and
also induced a significant IL-8 release (F ¼ 5:76, p ¼ 0:02).
Sotalol (103M) and propranolol (105M) did not block the
effect on IL-6 and IL-8 release induced by the two b-agonists
(106M).
Non-stimulated PBEC
Formoterol significantly increased the IL-6 (F ¼ 35:01,
p ¼ 0:0004) and IL-8 (F ¼ 27:80, p ¼ 0:0007) release
(Fig. 4). The stimulatory effect peaked at 108 M by a
10.6-fold increase of the IL-6 and 2.7-fold increase of the IL-
8 release (Fig. 4). Also salmeterol induced an increase in IL-6
(F ¼ 13:19, p ¼ 0:0069), and IL-8 (F ¼ 18:32, p ¼ 0:0004)
release. Also for salmeterol maximal cytokine release was
observed at 108 M, 7.0-fold for IL-6 and 2.6-fold for IL-8
(Fig. 4). The effect of formoterol and salmeterol was
blocked with propranolol (105 M) (Fig. 4).
Dust stimulated A549 cells
Formoterol induced an enhancement of dust stimulated IL-6
release in A549 cells (F ¼ 61:7, po0:0001) (Fig. 5a).
Formoterol enhanced dust-induced IL-8 release (F ¼ 6:33,
pp0:0001) only at the highest concentrations whereas
salmeterol did not influence dust-induced IL-6 and IL-8
release from A549 cells (Fig. 5b). The effect of formoterol
was not blocked with sotalol (103 M) or propranolol
(105 M).
Dust stimulated PBEC
Both formoterol and salmeterol enhanced dust-induced IL-6
release from PBEC (Fig. 6a). This effect reached its
maximum at 109 M after which a tendency towards less
enhancement was observed at higher concentrations
(Fig. 6a). Similar to formoterol the dose–response curve of
salmeterol-induced enhancement of IL-6 release following
dust stimulation was bell-shaped with a maximal effect at
109–107 M (Fig. 6a). When IL-6 response is expressed as a
function of increased b2-agonist concentration, r2 ¼ 0:57 for
formoterol and r2 ¼ 0:69 for salmeterol when analysed by
linear regression. Fitted to a regression line of the second
degree corresponding r2 are 0.78 and 0.84.
Formoterol yielded a slight enhancement of dust-induced
IL-8 release in PBEC (F ¼ 5:21, p ¼ 0:01) although no
dose–response relationship was observed (Fig. 6b). Also
salmeterol enhanced dust-induced IL-8 release in a non-
dose–response manner (F ¼ 3:29, p ¼ 0:004).
Propranolol (105 M) significantly blocked the b2-agonist-
induced enhancement of dust-induced IL-6 release in PBEC
(Fig. 6a). Since no clear enhancement of IL-8 release was
observed for either b-agonist no inhibition with propranolol
was found.
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K. Strandberg et al.1136Discussion
In the present study it has been shown that organic dust
from a swine barn is a strong stimulus for IL-6 and IL-8
release in normal bronchial epithelial cells (PBEC) and, as
previously shown, in human alveolar epithelial carcinoma
cells (A549). It was also demonstrated that b2-agonists
induce IL-6- and IL-8-release in PBEC and A549 cells and that
this effect was mediated by specific b2-adrenoceptor
mechanisms in PBEC only. In addition, in PBEC it was shown
that IL-6 release induced by organic dust was enhanced by
b2-adrenoceptor stimulation whereas no such enhancement
was found for IL-8 release.
The effect of b2-adrenoceptor stimulation on IL-6 and IL-8
release in PBEC was bell-shaped and reached its maximum
at 109–108 M and tended to decrease at the highest
agonist concentration (106 M). The attenuation of cytokine
release at the highest concentration was observed for both
salmeterol and formoterol and was reproduced in every
assay in a series of three experiments performed in
triplicates. The cytokine levels assessed in the present
study reflect the cumulative release induced by theb2-agonists during 24 h. We did not perform time kinetic
experiments in order to evaluate whether cytokines were
released continuously during the 24 h of incubation or if the
release levelled off with time. The reason for the bell-
shaped dose–response relationship is not clear. Desensitiza-
tion due to long exposure may limit the effect of the
agonists, and this may depend on the structure of the
agonist, the cell type and the outcome measures.18 This
would likely result in a reduced cumulative cytokine release
during 24 h of incubation.
It is known that exposure to organic dust from swine
houses induces production and release of pro-inflammatory
cytokines, such as IL-1 b and TNF both in vivo and in
vitro.9,10,19 It has previously been shown that IL-1b and TNF
attenuate the airway smooth muscle relaxation induced by
b-adrenoceptor activation.20 The probable mechanism of
this effect is that IL-1b and TNF induce prostaglandin
E2-release in human airway smooth muscle cells which in
turn induces b-adrenergic hyporesponsiveness by hetero-
logous desensitization of the b-adrenoceptor.21 There is thus
a possibility that b2-adrenoceptors on PBEC activated by
organic dust and b2-agonists are down-regulated by both
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B2-agonists and airway epithelial cells 1137homologous and heterologous mechanisms. This additive
effect on desensitization may also contribute to the bell
shaped dose–response curve with attenuation of the
response of the two long-acting b2-agonists at the highest
concentration.
Only salmeterol induced IL-6 release, whereas both
b2-agonists induced IL-8 release in non-stimulated A549
cells and only formoterol enhanced dust-induced IL-6 and IL-
8 release in A549 cells. The discrepancy between the effect
of salmeterol and formoterol and the lack of inhibition of a
b-blocker in non-stimulated and dust-stimulated A549 cells
strongly suggest that the observed effects were not
mediated by b-adrenoceptor mechanisms. Since we did not
observe a blocking effect with sotalol in the experiments
with A549 cells, we made additional experiments with
another b-blocker, propranolol, which also failed to block
the effect of the b-agonists. In a pilot study we showed that
sotalol had a blocking effect on PBEC (data not shown).
Nevertheless, we preferred to use propranolol in the
subsequent experiments since this b-blocker seems to be
the most frequently used by others which makes compar-
isons with results obtained by other research groups morefeasible. We demonstrated that the solvents (hydrochloric
acid for formoterol and phosphate buffer/saline for salme-
terol) did not influence cytokine release at concentrations
corresponding to a b2-agonist concentration of 10
6 M. The
stimulation of IL-6 and IL-8 release by salmeterol and
formoterol in A549 cells was thus drug specific although not
specifically mediated by b2-adrenoceptor mechanisms. From
these experiments it can be concluded that, although A549
cells possess b2-adrenoceptors
22 and are capable of increas-
ing intracellular levels of cyclic AMP following stimulation
with forskolin,23 the coupling between the receptor and the
effector in A549 cells seems to fail as far as IL-6 and IL-8
release are concerned. Whether this is a general observation
in human type II alveolar epithelial cells or if it is restricted
to the carcinoma cell line is not clear. We conclude, from
the present findings that signal transduction induced by
b2-adrenoceptor activation may be altered in this trans-
formed cell line (A549) while being intact in normal
bronchial epithelium (PBEC).
It has previously been shown that b2-agonist stimulation
induces IL-8 release in bronchial epithelial cells3,24 but, to
our knowledge, the present data are the first to demon-
strate that b2-agonists also influence and enhance IL-6
release in bronchial epithelial cells. We demonstrated
that the b2-agonist-mediated stimulation of IL-6- and
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conducted in triplicates and expressed as mean and SEM.
*po0:05, **po0:01, and ***po0:001 compared with control.
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Figure 6 Dose–response curves for IL-6 (panel a) and IL-8
(panel b) release induced by formoterol and salmeterol
(1013–106 M) in dust-stimulated PBEC. The cytokine release
is expressed as percent of control, i.e. PBEC stimulated with
dust, without drugs. Data are based on three experiments
conducted in triplicates and expressed as mean and SEM.
*po0:05, **po0:01, and ***po0:001 compared with control.
K. Strandberg et al.1138IL-8-release in non-stimulated and dust-stimulated PBEC
was blocked by propranolol which clearly indicates the
effects to be specific, i.e. mediated by a b2-adrenoceptor
mechanism. The organic dust-induced, dose-dependant
cytokine release from PBEC was similar to what has been
found in A549 cells.12,14 It was also demonstrated that the
onset of IL-6 release preceded that of IL-8, a finding which is
in accordance with previous results. Burvall et al.25 found
that mRNA expression for IL-6 appeared and levelled off
prior to that of IL-8 in A549 cells activated with organic dust.
Although both salmeterol- and formoterol induced IL-6
and IL-8 release in un-stimulated PBEC, the b2-agonist
enhanced the release of IL-6 only and did not influence IL-8
release in dust-stimulated PBEC. One conceivable explana-
tion to this finding is that the release of IL-8 may be maximal
after dust stimulation leaving no space for further enhance-
ment by the b2-agonists. The lack of an added effect of the
b2-agonists to that of the dust may also indicate a low
sensitivity of IL-8 release to b2-adrenoceptor stimulation.
This would implicate that b2-adrenoceptor activation
comprises a weak stimulus for IL-8 release in the presence
of stronger stimuli such as organic dust.
Dust from swine confinement buildings contains feed and
bedding material, epithelial cells from the pigs
(dander), faecal material including micro-organisms, bothGram-negative and Gram-positive bacteria.26,27 Three hours
of exposure in a pig barn induces release of IL-6 and IL-8 in
the airways assessed by bronchoalveolar lavage.8,9 Dust,
Gram-positive bacteria and soluble components from the
bacteria are potent stimuli for IL-6 and IL-8 release in A549
cells and human alveolar macrophages.28 It is thus likely
that the airway reaction to exposure in a pig barn is caused
by microbial products and airway epithelial cells are most
probably involved in the airway response to inhaled organic
dust. The airway cellular reaction to dust exposure is,
similar to what is observed during acute exacerbations of
asthma, characterized by neutrophils and exposure to pig
house dust may serve as a model for innate immunity
activation. From other studies it seems clear that
b2-agonists are capable of interaction with the inflammatory
process in asthma29–31 and it could not be excluded that
inhalation of b2-agonists during acute exacerbations of
asthma may interfere with the inflammatory response
induced by the agents that triggered the asthma attack.
How this may influence the clinical outcome of treatment is,
however, far from clear.Acknowledgements
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